1.

Record Nr.

UNINA9910822830003321

Titolo

Scientific standards for studies on modified risk tobacco products / / Institute of Medicine of the National Academies

Pubbl/distr/stampa

Washington, D.C., : National Academies Press, 2012

ISBN

1-280-38022-5

9786613558138

0-309-22399-7

Edizione

[1st ed.]

Descrizione fisica

1 online resource (370 p.)

Disciplina

616.86506

Soggetti

Tobacco - Risk assessment - Research - United States

Tobacco use - Health aspects - Research - United States

Products liability - Tobacco - United States

Nicotine addiction - Research - United States

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

"Committee on Scientific Standards for Studies on Modified Risk Tobacco Products, Board on Population Health and Public Health Practice."

Nota di bibliografia

Includes bibliographical references.

Nota di contenuto

""Front Matter""; ""Reviewers""; ""Preface""; ""Contents""; ""Acronyms and Abbreviations""; ""Summary""; ""1 Introduction""; ""2 Governance and Conduct of Studies""; ""3 Evidence Base and Methods for Studying Health Effects""; ""4 Methods for Investigating Addictive Potential""; ""5 Methods for Studying Risk Perception and Risk Communication""; ""6 Decision Making and Oversight of MRTP Studies: Findings and Recommendations""; ""Appendix A: Section 911 of the Family Smoking Prevention and Tobacco Control Act of 2009""

""Appendix B: Chapters 1 and 2 from *Evaluation of Biomarkers andSurrogate Endpoints in Chronic Disease*""""[Appendix B] 1 Introduction""; ""[Appendix B] 2 Review: Evaluating and Regulating Biomarker Use""; ""Appendix C: Committee Biographies""; ""Appendix D: Meeting Agendas""

Sommario/riassunto

"Smoking-related diseases kill more Americans than alcohol, illegal drugs, murder and suicide combined. The passage of the Family Smoking Prevention and Tobacco Control Act of 2009 gave the FDA



authority to regulate "modified risk tobacco products" (MRTPs), tobacco products that are either designed or advertised to reduce harm or the risk of tobacco-related disease. MRTPs must submit to the FDA scientific evidence to demonstrate the product has the potential to reduce tobacco related harms as compared to conventional tobacco products. The IOM identifies minimum standards for scientific studies that an applicant would need to complete to obtain an order to market the product from the FDA."--Publisher's description.